Adaptimmune Gets Access to Priority Medicines Regulatory Support for its SPEAR T-cell Therapy

Adaptimmune Therapeutics plc

revealed Thursday that the European Medicines Agency (EMA) has given permission to access to its newly-established Priority Medicines (PRIME) regulatory initiative for its SPEAR T-cell therapy. According to the company, the drug focuses on NY-ESO for the treatment of HLA-A0201, HLA-A0205, or HLA-A0206 allele positive patients with inoperable or metastatic synovial sarcoma who have got prior chemotherapy and whose tumor expresses the NY-ESO-1 tumor antigen. The company indicated that PRIME initiative offers help to maximize regulatory applications and quicken the review of medicines, which address increased unmet requirements. Adaptimmune said that its SPEAR T-cell candidates were novel cancer immunotherapies, which were engineered to focus and destroy cancer cells by strengthening a patient's natural T-cell response. The company added that T-cells are a type of white blood cell, which plays a key role in a person's immune response. The company indicated that its objective is to exploit the power of the T-cell and, through its several therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with solid and hematologic cancers. Its Chief Medical Officer, Rafael Amado, said, "Access to the PRIME initiative represents an important regulatory opportunity for us. It can provide early engagement on the development program with potential for accelerated assessment of data to companies like Adaptimmune who are developing new treatment modalities for patients in Europe with few or no treatment options." The stock fell $0.11 or 1.40 percent at $7.93 on Thursday.